Versuchen GOLD - Frei
Policy Reforms Give India's MedTech Sector a Global Edge
BioSpectrum Asia
|BioSpectrum Asia Nov 2025
Since medical technology (MedTech) is a sunrise industry, the government is giving it priority to support patient-centric growth, while also concentrating on lowering reliance on imports and aligning regulations with international norms. With a focus on capital, incubation, talent development, and market access, the Indian government has started a broad range of programmes to support MedTech firms. This article examines governmental and regulatory efforts, emphasizing how policy-driven assistance is helping MedTech businesses become more globally competitive.
-
The MedTech sector in India represents a dynamic intersection of healthcare, engineering, and digital innovation, encompassing devices, diagnostics, and software solutions aimed at improving patient outcomes, reducing costs, and enhancing accessibility. From wearable health monitors to AI-driven diagnostic tools, MedTech startups are pivotal in addressing India's vast healthcare challenges, including a burgeoning population of over 1.4 billion, rising chronic diseases, and unequal access to medical services in rural areas.
The sector, valued at approximately Rs 1,02,660 crore ($12 billion) in fiscal year 2024, is projected to reach Rs 4,27,750 crore ($50 billion) by 2050, growing at a compound annual growth rate (CAGR) of around 15 per cent. This growth is fueled not only by market demand but also by robust government and regulatory support, which has transformed India from a net importer of medical devices to an aspiring global hub.
Historically, India's MedTech landscape was dominated by multinational corporations, with domestic firms contributing less than 20 per cent to the market. However, post-2014, initiatives like 'Make in India' and 'Aatmanirbhar Bharat' have shifted the focus toward indigenous innovation. The government recognises MedTech as a sunrise sector, prioritising it to enable patient-centric growth, while focusing on regulatory alignment with global standards, and reducing import dependency. The Indian government has launched a multifaceted ecosystem of initiatives to nurture MedTech startups, focusing on funding, incubation, skill development, and market access.
Government and Regulatory Initiatives Supporting MedTech Startups
MedTech Mitra
Diese Geschichte stammt aus der BioSpectrum Asia Nov 2025-Ausgabe von BioSpectrum Asia.
Abonnieren Sie Magzter GOLD, um auf Tausende kuratierter Premium-Geschichten und über 9.000 Zeitschriften und Zeitungen zuzugreifen.
Sie sind bereits Abonnent? Anmelden
WEITERE GESCHICHTEN VON BioSpectrum Asia
BioSpectrum Asia
India–EU FTA Paves Way for Expanded Healthcare Trade
On January 27, 2026, after years of negotiations, India and the European Union announced a landmark Free Trade Agreement.
4 mins
BioSpectrum Asia March 2026
BioSpectrum Asia
PreferCo and Glatt to open CoE for precision fermentation bioprocess scale-up in India
In a major boost to Government of India's BioE3 push, German major Glatt and India-based startup PreferCo have announced the launch of \"PreferCo-Glatt Centre of Excellence (CoE) for Bioprocess Scale-Up\" in Hyderabad's Genome Valley.
1 min
BioSpectrum Asia March 2026
BioSpectrum Asia
Women's Health Surge in APAC
The rising burden of diseases such as ovarian cancer, breast cancer, cervical cancer, infertility, etc. is emerging as the key driver of the women's healthcare market across the globe. While North America led the women healthcare market in 2025, Asia Pacific (APAC) is expected to witness the fastest growth this year onwards. As a result, governments across the APAC region, are recognising the importance of women's health and are launching initiatives, particularly under female leaders, to improve access to healthcare services. Moreover, a number of women-led startups are now developing new solutions to address this growing burden of women-associated diseases in the APAC region. Let's take a closer look.
6 mins
BioSpectrum Asia March 2026
BioSpectrum Asia
Hanchor Bio receives US FDA Orphan Drug Designation for HCB101 in gastric cancer
Taiwan-based biotech startup HanchorBio, Inc. has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to HCB101 for the treatment of gastric cancer.
1 min
BioSpectrum Asia March 2026
BioSpectrum Asia
Daiichi Sankyo names Dr John Tsai as Global Head of R&D
Japan-based Daiichi Sankyo Company has appointed Dr John Tsai to succeed Dr Ken Takeshita, who is stepping down as Global Head of R&D, effective April 1, 2026.
1 min
BioSpectrum Asia March 2026
BioSpectrum Asia
"The global trend is moving beyond centralised hubs toward distributed networks and domestic capability"
King Faisal Specialist Hospital & Research Centre (KFSHRC) and US-based Germfree Laboratories have announced a strategic partnership to develop Saudi Arabia's first fully integrated, modular Advanced Therapy Medicinal Product (ATMP) Manufacturing Campus.
4 mins
BioSpectrum Asia March 2026
BioSpectrum Asia
SEOUL'S RISKY DRUG PRICING RESET
Drug pricing has once again moved to the centre of policy debate in South Korea, with the government recently stepping back from its proposed generic drug pricing reform.
2 mins
BioSpectrum Asia March 2026
BioSpectrum Asia
Takeda and Iambic sign $1.7 B deal to advance AI driven design of small molecules
Iambic, a US-based clinical-stage life science and technology company developing novel medicines using its artificial intelligence (AI)-driven discovery and development platform, has announced a multi-year technology and discovery collaboration agreement with Japan-based Takeda Pharma that will use Iambic's industry leading AI drug discovery models to advance a select set of high-priority small molecule programmes, initially in Takeda's Oncology and Gastrointestinal and Inflammation therapeutic areas.
1 min
BioSpectrum Asia March 2026
BioSpectrum Asia
S.Biomedics announces partnership with Catalent to develop and manufacture TED-A9
US-based Catalent and South Korea-based S.Biomedics have announced a strategic partnership to support the development and manufacturing of TED-A9, S.Biomedics' allogeneic pluripotent stem-cell-derived ventral midbrain-specific dopaminergic precursor cell therapy being developed for the treatment of Parkinson's disease.
1 min
BioSpectrum Asia March 2026
BioSpectrum Asia
China revises drug administration regulations to spur innovation
China has revised regulations concerning drug administration in a bid to promote drug innovation, strengthen management of online sales of medicines and reinforce drug safety supervision.
1 min
BioSpectrum Asia March 2026
Listen
Translate
Change font size

